Tim Staudenmaier1, Irena Cenzer1, Alexander Crispin2, Helmut Ostermann1, Karin Berger3. 1. Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. 2. Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-Universität München, Munich, Germany. 3. Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. karin.berger@med.uni-muenchen.de.
Abstract
PURPOSE: Purpose of this study was to determine the impact of Oral Mucositis (OM) on health-related quality of life (HRQoL) and quality of life associated symptoms and functions in patients undergoing hematopoietic stem cell transplantation (HSCT). METHODS: Prospective, non-interventional single-center observational study at a German tertiary teaching hospital. Inpatient allogenic and autologous stem cell transplant patients ≥18-year-old with high-dose chemotherapy. OM was assessed with the WHO Oral Toxicity Scale, pain according to the Numeric Rating Scale (NRS) and the performance status using the ECOG Score. QOL was captured with the EORTC QLQ-C30 and the QLQ-OH15 questionnaires. RESULTS: Forty-five stem cell transplant patients (20 autologous, 25 allogenic) were enrolled between August 2016 and February 2017. Twenty-six (58%, 95% CI: 42% - 72%) patients developed OM (10 grade I, 4 grade II, 8 grade III, 4 grade IV). OM affected patients suffered more from pain, sore mouth and sensitive mouth. A lower physical functioning (34.5 vs 7.5, p = 0.003) and a lower oral health-related quality of life (24.3 vs 7.7, p = 0.006) was found in patients with OM development. There was found a positive correlation between the grade of OM and the NRS-value (r = 0.93, 95% CI: 0.89-0.96, p < 0.001). CONCLUSION: OM is associated with health-related quality of life and quality of life associated functions and symptoms. More research should be performed to find ways to prevent OM and to stabilize patients' quality of life during HSCT.
PURPOSE: Purpose of this study was to determine the impact of Oral Mucositis (OM) on health-related quality of life (HRQoL) and quality of life associated symptoms and functions in patients undergoing hematopoietic stem cell transplantation (HSCT). METHODS: Prospective, non-interventional single-center observational study at a German tertiary teaching hospital. Inpatient allogenic and autologous stem cell transplant patients ≥18-year-old with high-dose chemotherapy. OM was assessed with the WHO Oral Toxicity Scale, pain according to the Numeric Rating Scale (NRS) and the performance status using the ECOG Score. QOL was captured with the EORTC QLQ-C30 and the QLQ-OH15 questionnaires. RESULTS: Forty-five stem cell transplant patients (20 autologous, 25 allogenic) were enrolled between August 2016 and February 2017. Twenty-six (58%, 95% CI: 42% - 72%) patients developed OM (10 grade I, 4 grade II, 8 grade III, 4 grade IV). OM affected patients suffered more from pain, sore mouth and sensitive mouth. A lower physical functioning (34.5 vs 7.5, p = 0.003) and a lower oral health-related quality of life (24.3 vs 7.7, p = 0.006) was found in patients with OM development. There was found a positive correlation between the grade of OM and the NRS-value (r = 0.93, 95% CI: 0.89-0.96, p < 0.001). CONCLUSION: OM is associated with health-related quality of life and quality of life associated functions and symptoms. More research should be performed to find ways to prevent OM and to stabilize patients' quality of life during HSCT.
Entities:
Keywords:
Cancer treatment; HSCT; Health-related quality of life; Hematopoietic stems cell transplantation; Oral mucositis
Authors: Linda S Elting; Catherine Cooksley; Mark Chambers; Scott B Cantor; Ellen Manzullo; Edward B Rubenstein Journal: Cancer Date: 2003-10-01 Impact factor: 6.860
Authors: José Manuel Martinez; Dulcineia Pereira; Sérgio Chacim; Edgar Mesquita; Inês Sousa; Ângelo Martins; Teresa Azevedo; José Mário Mariz Journal: Support Care Cancer Date: 2014-04-18 Impact factor: 3.603
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Marianne J Hjermstad; Mia Bergenmar; Kristin Bjordal; Sheila E Fisher; Dirk Hofmeister; Sébastien Montel; Ourania Nicolatou-Galitis; Monica Pinto; Judith Raber-Durlacher; Susanne Singer; Iwona M Tomaszewska; Krzysztof A Tomaszewski; Irma Verdonck-de Leeuw; Noam Yarom; Julie B Winstanley; Bente B Herlofson Journal: Support Care Cancer Date: 2016-04-25 Impact factor: 3.603
Authors: J R Passweg; H Baldomero; P Bader; C Bonini; S Cesaro; P Dreger; R F Duarte; C Dufour; J Kuball; D Farge-Bancel; A Gennery; N Kröger; F Lanza; A Nagler; A Sureda; M Mohty Journal: Bone Marrow Transplant Date: 2016-02-22 Impact factor: 5.483
Authors: Isabella Lima Arrais Ribeiro; Ricardo Dias de Castro; Raphael Cavalcante Costa; Lecidâmia Cristina Leite Damascena; Nyellisonn Nando Nóbrega de Lucena; Paula Maria Bezerra Maracajá; Fabio Gomes Dos Santos; Eliane Batista de Medeiros Serpa; Simone Alves Sousa; Ana Maria Gondim Valença Journal: Eur J Pediatr Date: 2021-03-22 Impact factor: 3.183
Authors: Paula Maria Maracajá Bezerra; Maria Eduarda Alves Sampaio; Fabio Gomes Dos Santos; Isabella Lima Arrais Ribeiro; Bianca Marques Santiago; Simone Alves de Sousa; Ana Maria Gondim Valença Journal: Support Care Cancer Date: 2021-06-29 Impact factor: 3.603